drugset
drugset / Trial / NCT02662764

Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

NCT02662764 ↗

Phase 3 Completed 320 enrolled Talphera, Inc
NaSingle-groupOpen-labelTreatment

Summary

Study to evaluate the overall performance of the Zalviso System™ (sufentanil sublingual tablet system) 15 mcg

Timeline

Start
2016-09-28
Primary completion
2017-04-14
Completion
2017-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sufentanil Other / unclassified 15 ug Other

Indications

No indication recorded.